CA2440480A1 - Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions - Google Patents

Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions Download PDF

Info

Publication number
CA2440480A1
CA2440480A1 CA002440480A CA2440480A CA2440480A1 CA 2440480 A1 CA2440480 A1 CA 2440480A1 CA 002440480 A CA002440480 A CA 002440480A CA 2440480 A CA2440480 A CA 2440480A CA 2440480 A1 CA2440480 A1 CA 2440480A1
Authority
CA
Canada
Prior art keywords
alpha
ketoalkanoic acid
cytokine
ethyl pyruvate
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002440480A
Other languages
English (en)
French (fr)
Inventor
Mitchell P. Fink
Luis Ulloa
Kevin J. Tracey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Feinstein Institutes for Medical Research
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2440480A1 publication Critical patent/CA2440480A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA002440480A 2001-03-15 2002-03-15 Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions Abandoned CA2440480A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27627901P 2001-03-15 2001-03-15
US60/276,279 2001-03-15
PCT/US2002/008283 WO2002074301A1 (en) 2001-03-15 2002-03-15 Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions

Publications (1)

Publication Number Publication Date
CA2440480A1 true CA2440480A1 (en) 2002-09-26

Family

ID=23055992

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002440480A Abandoned CA2440480A1 (en) 2001-03-15 2002-03-15 Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions

Country Status (6)

Country Link
US (2) US6943190B2 (enExample)
EP (1) EP1379230A4 (enExample)
JP (1) JP2004528307A (enExample)
AU (1) AU2002255805B2 (enExample)
CA (1) CA2440480A1 (enExample)
WO (1) WO2002074301A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
EP1379230A4 (en) * 2001-03-15 2009-01-21 Univ Pittsburgh METHOD OF USE OF PYRUVATE AND / OR ITS DERIVATIVES FOR TREATING CYTOKINE-ORGANIZED INFLAMMABLE CONDITIONS
EP1377339A4 (en) * 2001-04-04 2006-05-31 Critical Therapeutics Inc PROCEDURE FOR PREVENTING AKUTER NIERENINSUFFIZIENZ
US6900218B2 (en) 2001-05-03 2005-05-31 Galileo Pharmaceuticals, Inc. Pyruvate derivatives
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US8076373B2 (en) * 2001-09-11 2011-12-13 North Cell Pharmacetical Method for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite
US7122578B2 (en) * 2001-09-11 2006-10-17 Alain Martin Method and composition for treating mammalian diseases and injuries which cause pain, erythema, swelling, crusting, ischemia scarring and excess white blood cell infiltration
US20060035851A1 (en) * 2002-07-03 2006-02-16 Bianchi Marco E Use of hmgb1 in the treatment of tissue damage and or to promote tissue repair
US7273872B2 (en) * 2002-12-06 2007-09-25 The Feinstein Institute For Medical Research Inhibition of inflammation using α 7 receptor-binding cholinergic agonists
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
CA2528144A1 (en) * 2003-06-09 2005-01-20 Mitchell P. Fink Method for treating acute pancreatitis
EP1635806B1 (en) * 2003-06-13 2008-05-28 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method for treating alcoholic hepatitis
ES2222093A1 (es) * 2003-07-01 2005-01-16 Advanced In Vitro Cell Technologies, S.L. Metodo para el almacenamiento y/o transporte de cultivos celulares in vitro.
US7288250B2 (en) 2003-09-11 2007-10-30 Critical Therapeutics, Inc. Monoclonal antibodies against HMGB1
CA2543779A1 (en) * 2003-10-24 2005-05-06 Medtronic, Inc. Techniques to treat neurological disorders by attenuating the production of pro-inflammatory mediators
EP1814576A2 (en) * 2004-07-20 2007-08-08 Critical Therapeutics, Inc. Combination therapies of hmgb and complement inhibitors against inflammation
US20060253100A1 (en) 2004-10-22 2006-11-09 Medtronic, Inc. Systems and Methods to Treat Pain Locally
EP1924327A2 (en) 2005-04-15 2008-05-28 Biomac Privatinstitut für medizinische und Zahnmedizinische Forschung, Entwicklung und Diagnostik GmbH Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use to combat cancer
WO2007011606A2 (en) * 2005-07-18 2007-01-25 Critical Therapeutics, Inc. USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
NZ572649A (en) * 2006-04-12 2011-03-31 Ranya L Alexander Compositions comprising pyruvate alkyl esters and uses thereof
US7754247B2 (en) * 2007-05-29 2010-07-13 University Of South Carolina Resuscitation fluid
US8211943B2 (en) * 2007-08-08 2012-07-03 Alain Martin Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells
US8114907B2 (en) * 2007-08-08 2012-02-14 Cellular Sciences Inc Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells
US8815946B2 (en) * 2008-01-25 2014-08-26 University of Pittsburgh—of the Commonwealth System of Higher Education Inhibition of proliferation and fibrotic response of activated corneal stromal cells
WO2009116546A1 (ja) * 2008-03-18 2009-09-24 国立大学法人 岡山大学 興奮性化学伝達調節剤およびそのスクリーニング法
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US8426634B2 (en) 2008-11-20 2013-04-23 Chd Bioscience, Inc. α-keto peracids and methods for producing and using the same
US8445717B2 (en) * 2008-11-20 2013-05-21 Chd Bioscience, Inc. α-Keto alkylperacids and methods for producing and using the same
WO2010078322A1 (en) 2008-12-30 2010-07-08 Hill's Pet Nutrition, Inc. Use of lipoic acid for treating or preventing degenerative joint conditions, osteoarthritis, cartilage damage, and related disorders in companion animals
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
US9173422B2 (en) * 2009-12-29 2015-11-03 Hill's Pet Nutrition, Inc. Compositions including pyruvate for companion animals and methods of use thereof
US11284621B2 (en) 2010-04-15 2022-03-29 Armis Biopharma, Inc. Compositions comprising peroxyacid and methods for producing and using the same
US9044527B2 (en) 2011-02-17 2015-06-02 Chd Bioscience, Inc. Wound care products with peracid compositions
EP2675441A4 (en) * 2011-02-17 2014-12-31 Chd Bioscience Inc COMPOSITIONS WITH PEROXY-ALPHA-KETOCARBOXYLIC ACID AND METHOD FOR THE PRODUCTION AND THEIR USE
EP2676675B1 (en) * 2011-02-18 2019-04-10 Stemdr Inc. Composition containing inducer of sirt1 expression for preventing or treating sepsis or septic shock
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
US9244074B2 (en) * 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
JP2015533375A (ja) 2012-10-18 2015-11-24 シーエイチディー・バイオサイエンス，インコーポレーテッド ペルオキシ酸を含む組成物
US9578879B1 (en) 2014-02-07 2017-02-28 Gojo Industries, Inc. Compositions and methods having improved efficacy against spores and other organisms
DE102017131059A1 (de) * 2017-12-22 2019-06-27 Christiane Kappert Physiologisch verträgliche Lösung mit einem Gehalt an Pyruvat und Glycin, eine Pyruvat und Glycin enthaltende Zusammensetzung und Verfahren zu deren Herstellung
EP3797766A1 (en) * 2019-09-24 2021-03-31 Evonik Operations GmbH Compositions for use in reducing inflammation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2307075A (en) * 1940-08-02 1943-01-05 Carbide And Carbon Chemicais C Vinyl resin composition
US4105782A (en) * 1975-03-07 1978-08-08 Yu Ruey J Treatment of acne and dandruff
US4197316A (en) * 1975-07-23 1980-04-08 Scott Eugene J Van Treatment of dry skin
JPS539847A (en) * 1976-07-15 1978-01-28 Akishima Kagaku Kogyo Stabilized halogenncontained resin composition
US4234599A (en) * 1978-10-04 1980-11-18 Scott Eugene J Van Treatment of skin keratoses with α-hydroxy acids and related compounds
US4246261A (en) * 1979-08-09 1981-01-20 Scott Eugene J Van Additives enhancing topical corticosteroid action
DE3133132A1 (de) * 1981-08-21 1983-03-03 Schweiger Hubert Terpene in synergistisch wirkenden kombinationen mit (alpha)-ketomono- und/oder (alpha)-ketodicarbonsaeuren und/oder deren mono- bzw. mono- und/oder diester und verwendung dieser pflanzlichen wirkstoffkombinationen als bioaktive mittel in arznei-, kosmetischen und dermatologischen mitteln
DE3581407D1 (de) 1985-09-06 1991-02-21 Nestle Sa Bewahrung lebender gewebe.
US6051609A (en) 1997-09-09 2000-04-18 Tristrata Technology, Inc. Additives enhancing the effect of therapeutic agents
AU8539491A (en) * 1990-09-21 1992-04-15 Regents Of The University Of Minnesota Pyruvate solutions to counteract acute renal failure
US5210098A (en) 1990-09-21 1993-05-11 Regents Of The University Of Minnesota Use of pyruvate to treat acute renal failure
US5648380A (en) 1991-03-01 1997-07-15 Warner-Lambert Company Anti-inflammatory wound healing compositions and methods for preparing and using same
WO1993006726A1 (en) 1991-09-30 1993-04-15 Mackenzie Walser Methods for treatment of free-radical-mediated tissue injury
DE4415581C2 (de) * 1994-05-04 1995-12-07 Voith Gmbh J M Papier-Streichvorrichtung
US5536751A (en) * 1994-05-09 1996-07-16 The United States Of America As Represented By The Secretary Of The Army Pharmaceutical alpha-keto carboxylic acid compositions method of making and use thereof
US5480909A (en) 1994-08-08 1996-01-02 University Of Pittsburgh Medical Center Method for inhibiting generation of free-radicals
US5908611A (en) 1995-05-05 1999-06-01 The Scripps Research Institute Treatment of viscous mucous-associated diseases
MX9703653A (es) * 1995-09-19 1998-07-31 Cellular Sciences Inc Composicion y metodo para tratar enfermedades mamiferas ocasionadas por la respuesta inflamatoria.
US5798388A (en) * 1996-09-06 1998-08-25 Cellular Sciences, Inc. Method and composition for treating mammalian diseases caused by inflammatory response
US6086789A (en) 1996-03-18 2000-07-11 Case Western Reserve University Medical uses of pyruvates
US5756469A (en) 1996-07-26 1998-05-26 Beale; Paxton K. Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
US6417231B1 (en) * 1996-12-23 2002-07-09 Frank L. Greenway Method and composition for delivering therapeutically effective amounts of pyruvate to a mammal
EP1183022B1 (en) 1999-05-14 2010-12-29 Cellular Sciences, Inc. Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response
US6846842B2 (en) * 1999-10-07 2005-01-25 Beth Israel Deconess Medical Center, Inc. Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion
CA2386461A1 (en) * 1999-10-07 2001-04-12 Masstrace, Inc. Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion
EP1379230A4 (en) * 2001-03-15 2009-01-21 Univ Pittsburgh METHOD OF USE OF PYRUVATE AND / OR ITS DERIVATIVES FOR TREATING CYTOKINE-ORGANIZED INFLAMMABLE CONDITIONS

Also Published As

Publication number Publication date
EP1379230A4 (en) 2009-01-21
US20050245609A1 (en) 2005-11-03
US6943190B2 (en) 2005-09-13
AU2002255805B2 (en) 2005-03-24
WO2002074301A1 (en) 2002-09-26
EP1379230A1 (en) 2004-01-14
JP2004528307A (ja) 2004-09-16
US20040110833A1 (en) 2004-06-10

Similar Documents

Publication Publication Date Title
US6943190B2 (en) Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions
AU2002255805A1 (en) Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions
Molad Update on colchicine and its mechanism of action
CA2386990C (en) Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase
JP5919597B2 (ja) デオキシコール酸およびその塩類の製剤
EP2970280A1 (en) Methods for treating inflammation, autoimmune disorders and pain
AU2024227697A1 (en) Use of neutrophil elastase inhibitors in liver disease
KR20160113307A (ko) 당뇨병 및 간 질환의 치료를 위한 조성물들 및 방법들
KR100969634B1 (ko) 글루코사민 또는 글루코사민 유도체를 포함하는 아토피성피부염 치료용 조성물 및 이를 사용하여 아토피성 피부염을치료하는 방법
JPH07509003A (ja) トキソプラスマ症（ｔｏｘｏｐｌａｓｍｏｓｉｓ）の治療のための薬剤の製造のためのリファマイシン（ｒｉｆａｍｙｃｉｎ）誘導体の使用
AU744492B2 (en) A pharmaceutical composition active in reducing production of mcp-1 protein
WO2016163082A1 (ja) Ａｌａ類を含むウイルス感染症予防／治療剤
ZA200105275B (en) New use of melagatran.
PT2120919E (pt) Nova combinação para utilização no tratamento de perturbações inflamatórias
TW200306853A (en) Therapeutic agent for glomerular disease
KR20200010164A (ko) 신규한 글루타미닐 고리화효소 억제제 및 다양한 질환의 치료에서의 이의 용도
CA3144374A1 (en) Treatment comprising sglt inhibitors, e.g. sglt 1/2 inhibitors
US6653294B2 (en) Use of chitinous materials for inhibiting cellular nitric oxide production
CA2124912A1 (en) Therapeutic composition
US20200188379A1 (en) Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines
EP4125870A1 (en) Methods for the treatment of inflammation associated with infection
WO2021142450A1 (en) Suppression of inflammasome activation
JP2016147890A (ja) デオキシコール酸およびその塩類の製剤
EP1127574A1 (en) Use of chitinous materials for inhibiting cellular nitric oxide production
US5008291A (en) Method and composition for achieving chemotherapeutic activity

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead